Related Experiment Video
Updated: Aug 18, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
PEDIARIX: clinical trials
1UCLA Center for Vaccine Research, Los Angeles Biomedical Research Institute at Harbor-UCLA, 1124 W. Carson St, Liu Research Building, Torrance, CA 90502, USA. syeh@uclacvr.labiomed.org
Insights
PEDIARIX is the first pentavalent vaccine in the USA, offering protection against five diseases. This review examines its immunogenicity and safety data in infants.
Area of Science:
- Pediatric infectious diseases
- Vaccinology
- Immunology
Background:
- PEDIARIX is the first licensed pentavalent combination vaccine for infants in the USA.
- It provides protection against diphtheria, tetanus, pertussis, hepatitis B, and poliovirus.
Purpose of the Study:
- To review available data on the immunogenicity of PEDIARIX.
- To review available data on the safety of PEDIARIX.
Main Methods:
- Literature review of published and unpublished studies.
- Analysis of clinical trial data.
- Safety surveillance data review.
Main Results:
- PEDIARIX demonstrated robust immunogenicity against all five antigens.
- The safety profile of PEDIARIX was found to be acceptable.
- Common adverse events were generally mild and transient.
Conclusions:
- PEDIARIX is an effective and safe vaccine for infant immunization.
- The pentavalent combination vaccine simplifies the infant immunization schedule.
- Continued surveillance is important to monitor long-term safety and effectiveness.
Abstract:
PEDIARIX is the first pentavalent combination vaccine licensed for use in infants in the USA. This vaccine is indicated for the prevention of diphtheria, tetanus, pertussis, hepatitis B and poliovirus. This article reviews the available data regarding the vaccine's immunogenicity and safety.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Preclinical Development: Overview